Tirzepatide significantly reduces arterial stiffness (CAVI) in obese T2D patients, with dose-dependent effects
Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.
Abstract
Tirzepatide significantly decreased cardio-ankle vascular index (CAVI) from 8.5 to 7.8 in 24 obese T2D patients, alongside reductions in BMI and HbA1c.